A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: LY2886721
DRUG: Placebo

Sponsor

Eli Lilly and Company